Your browser doesn't support javascript.
loading
Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan.
Eto, Masatoshi; Kawano, Yoshiaki; Hirao, Yoshihiko; Mita, Koji; Arai, Yoichi; Tsukamoto, Taiji; Hashine, Katsuyoshi; Matsubara, Akio; Fujioka, Tomoaki; Kimura, Go; Shinohara, Nobuo; Tatsugami, Katsunori; Hinotsu, Shiro; Naito, Seiji.
Afiliación
  • Eto M; Department of Urology, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan. etom@kumamoto-u.ac.jp.
  • Kawano Y; Department of Urology, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan. yoshiaki.kawano@gmail.com.
  • Hirao Y; Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8521, Japan. hiraoyos@gmail.com.
  • Mita K; Department of Urology, Hiroshima City Asa Hospital, 2-1-1 Kabeminami, Asa, Kita-ku, Hiroshima, 731-0293, Japan. mita@plum.ocn.ne.jp.
  • Arai Y; Department of Urology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, 980-8575, Japan. yarai@uro.med.tohoku.ac.jp.
  • Tsukamoto T; Department of Urology, Sapporo Medical University, S1 W17, Chuo-ku, Sapporo, 060-8556, Japan. taijit@sapmed.ac.jp.
  • Hashine K; Department of Urology, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minamiumemoto-chou, Matsuyama, 791-0280, Japan. khashine@shikoku-cc.go.jp.
  • Matsubara A; Department of Urology, Institute of Biomedical & Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. matsua@hiroshima-u.ac.jp.
  • Fujioka T; Department of Urology, Iwate Medical University School of Medicine, 19-1 Uchimaru, Morioka, 020-8505, Japan. tomof@iwate-med.ac.jp.
  • Kimura G; Department of Urology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8602, Japan. gokimura@nms.ac.jp.
  • Shinohara N; Department of Urology, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, Sapporo, 060-8638, Japan. nozomis@mbj.nifty.com.
  • Tatsugami K; Department of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. ktatsu@uro.med.kyushu-u.ac.jp.
  • Hinotsu S; Department of Phamacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshida-Konoe-sho, Sakyo-ku, Kyoto, 606-8501, Japan. hinotsus@cc.okayama-u.ac.jp.
  • Naito S; Department of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. naito@uro.med.kyushu-u.ac.jp.
BMC Cancer ; 15: 667, 2015 Oct 09.
Article en En | MEDLINE | ID: mdl-26452347
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Métodos Terapéuticos y Terapias MTCI: Terapias_biologicas / Aromoterapia Asunto principal: Carcinoma de Células Renales / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias Renales Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies País/Región como asunto: Asia Idioma: En Revista: BMC Cancer Año: 2015 Tipo del documento: Article País de afiliación: Japón
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Métodos Terapéuticos y Terapias MTCI: Terapias_biologicas / Aromoterapia Asunto principal: Carcinoma de Células Renales / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias Renales Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies País/Región como asunto: Asia Idioma: En Revista: BMC Cancer Año: 2015 Tipo del documento: Article País de afiliación: Japón